Literature DB >> 7679086

Interferon suppresses erythromycin metabolism in rats and human subjects.

P I Craig1, M Tapner, G C Farrell.   

Abstract

Interferon down-regulates expression of cytochrome P-450 3A in male rats. This study explored the hypothesis that interferon therefore decreases the metabolism of drugs catalyzed by cytochrome P-450 3A. Initial experiments in male rats used microsomal erythromycin N-demethylase activity as a probe for cytochrome P-450 3A catalytic activity. After administration of rat interferon-gamma, erythromycin metabolism was impaired (53% of control; p < 0.01). This change correlated with the decline in cytochrome P-450 3A-dependent androstenedione 6 beta-hydroxylase activity, indicating that the decrease in erythromycin N-demethylase activity could be attributed to interferon-mediated suppression of cytochrome P-450 3A. We then used the [14C]N-methyl erythromycin breath test to assess the activity of hepatic cytochrome P-450 3A in rats and human subjects before and after a single dose of interferon. In rats, rat interferon-gamma decreased erythromycin metabolism to 57% of control (p < 0.005). In the human study, six patients with chronic active hepatitis C and four healthy controls were examined 20 to 26 hr after receiving a subcutaneous injection of human interferon-alpha 2b. Interferon produced a small decrease (median = 15%; range = 3% to 35%) in erythromycin metabolism (p < 0.05), as determined by 2-hr excretion of 14CO2 in the breath. Thus interferon-mediated suppression of cytochrome P-450 3A is less strong in human subjects than in male rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679086

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

1.  Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha.

Authors:  Makrem Ben Reguiga; Laurence Bonhomme-Faivre; Simone Orbach-Arbouys; Robert Farinotti
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 3.  CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors:  Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

Review 4.  Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions.

Authors:  Pankajini Mallick; Guncha Taneja; Bhagavatula Moorthy; Romi Ghose
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-02-22       Impact factor: 4.481

5.  Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients.

Authors:  B C Israel; R A Blouin; W McIntyre; S I Shedlofsky
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

6.  Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.

Authors:  Stéphane Mouly; Nathalie Rizzo-Padoin; Guy Simoneau; Céline Verstuyft; Guy Aymard; Cécile Salvat; Isabelle Mahé; Jean-François Bergmann
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

7.  Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.

Authors:  Karin Hellman; Ewa Roos; Anna Osterlund; Anneli Wahlberg; Lars L Gustafsson; Leif Bertilsson; Sten Fredrikson
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 8.  Pharmacokinetic drug interactions with antimicrobial agents.

Authors:  J G Gillum; D S Israel; R E Polk
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

Review 9.  Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.

Authors:  Lucy Darakjian; Malavika Deodhar; Jacques Turgeon; Veronique Michaud
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

10.  Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes.

Authors:  Dirk Theile; Lelia Wagner; Cindy Bay; Walter Emil Haefeli; Johanna Weiss
Journal:  Pharmaceutics       Date:  2021-05-28       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.